In early 2023, the complement C3 inhibitor, pegcetacoplan (Syfovre, Apellis Pharmaceuticals, NDA 217171), was approved by the FDA for the treatment of the advanced stage of AMD, or GA, which was followed soon after by the approval of the complement C5 inhibitor avacincaptad pegol (Izervay, Astellas, NDA 217225). Here, C5 is linked to age-related macular degeneration.